Certara, Inc. — Company profile
Healthcare · Health Information Services · United States
Last price 11.2 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.71B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Details
| Name | Certara, Inc. |
| Sector | Healthcare |
| Industry | Health Information Services |
| Employees | 1576 |
| Founded | 2008 |
| Ipo Date | 2020-12-11 |
| Ceo | Jon Resnick |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 23.00 |
| Isin | US15687V1098 |
| Cusip | 15687V109 |
| Cik | 0001827090 |
| Sic | 7372 |
Key executives
| Name | Title |
|---|---|
| Jon Resnick | Chief Executive Officer and Director |
| Dr. Robert P. Aspbury Ph.D. | President of Certara Predictive Technologies |
| Leif E. Pedersen | Senior Advisor |
| Dr. Adrian K. McKemey Ph.D. | President of Drug Development Solutions |
| Julien Perrier | President and Chief Commercial Officer |
| Faiz Mohammed | Interim Chief Financial Officer, Senior Vice President of Finance, Treasurer and Principal Financial and Accounting Officer |
| Dr. Christopher Bouton Ph.D. | Chief Technology Officer and Chief AI Officer |
| Eric Jahn | Chief Information Officer |
| Daniel D. Corcoran | Senior Vice President, General Counsel and Secretary |
| Ron DiSantis | Senior Vice President of Corporate Development |
Contact
| Address | 4 Radnor Corporate Center, Suite 350, Radnor, Pennsylvania 19087, United States |
| Phone | 415 237 8272 |
| Website | https://www.certara.com |